GVHD comprises a spectrum of diseases following hematopoietic SCT (HSCT), caused by the graft recognition of allogeneic Ag on host tissue cells with subsequent inflammation and structural tissue damage. The host target cells are mostly epithelial in nature, with only rare cases of manifestations in mesenchymal tissues. GVHD may, however, mimic any and even rare forms of autoimmune disease. Here we report two cases of retroperitoneal fibrosis (RPF) in allogeneic transplant recipients, in both cases associated with extensive chronic GVHD, suggesting that RPF may be considered as a manifestation of GVHD.
The first patient was a 52-year-old man with anaplastic lymphoma kinase-negative anaplastic large T-cell lymphoma, who experienced relapse 14 months after dose-dense CHOEP primary chemotherapy. PBSCT from a matched unrelated donor was performed following conditioning treatment with fludarabine, CY and BU. 1 The post-transplant course was complicated by severe chronic GVHD, with significant manifestations in more than two organs starting 8 months after transplantation. Symptoms included initial maculopapular rash of the whole integument, lichenoid lesions in the buccal mucosa and keratoconjunctivitis sicca of both eyes. Immunosuppressive treatment with systemic prednisolone and CsA with doses adjusted to maintain levels of 200 ng/mL did not achieve an adequate therapeutic response. After the addition of mycophenolate mofetil 1 g daily, the cutaneous and oral symptoms ameliorated, whereas ocular GVHD failed to respond. Five years after transplantation, the patient was still under immunosuppressive therapy with CsA 125 mg twice daily and prednisolone 7.5 mg daily. Melanoderma of the whole skin, nail dystrophy and sicca syndrome of the eyes persisted as clinical manifestations of chronic GVHD. At this time, the patient presented with a new onset of diffuse lower abdominal pain. Exploratory laparotomy revealed small-bowel obstruction due to RPF, and fibrotic tissue resection with adhesiolysis was performed. Histology was consistent with the diagnosis of RPF without evidence for malignancy ( Figure 1a ). Serum levels of IgG4 were found to be elevated (1.72 g/L; normal range: 0.08-1.40 g/L), persisting for 4 years after the event. Although overt pancreatitis did not occur, the patient developed symptoms of exocrine and endocrine pancreas impairment. Under continued immunosuppression with initially increased, then gradually tapered doses of steroids and CsA at trough-levels to spare steroids, follow-up was unremarkable without any further abdominal complications up to 8 years after SCT. Dermal and ocular symptoms of chronic GVHD were stable under continued immunosuppressive therapy.
The second patient was a 36-year-old man who underwent PBSCT from a matched unrelated donor for blast-phase CML after conditioning with BU, CY and anti-thymocyte globulin. The patient also experienced severe chronic GvHD with mucocutaneous, ocular and hepatic manifestations, starting 6 months after transplantation. Systemic immunosuppressive therapy with systemic prednisolone and tacrolimus at trough-levels of 10 ng/mL resulted in normalization of liver function tests, and topical treatment of keratoconjunctivitis sicca and of the sclerotic skin involvement of the lower legs prevented progression. Four years after transplant, the patient described sacral back pain; at that time the patient exhibited distinct manifestations of chronic GVHD, such as nail dystrophy, dry eyes and sclerotic lesions of both lids, and received continued therapy with low-dose systemic prednisolone and tacrolimus at trough-levels. Radiographic diagnosis showed a diffuse retroperitoneal tissue mass covering the iliac vessels and right ureter, which was associated with hydronephrosis. Magnetic resonance imaging (MRI) confirmed the diagnosis of RPF (Figure 1b) . Ureteral stenting was placed and immunosuppressive therapy was re-escalated to a dose of 1 mg/kg body weight, leading to disease stabilization. Repeated imaging studies documented a slight regress of the RPF over the 1. Documentation of RPF. The biopsy specimen of peritoneal tissue from index patient 1 revealed enlarged layers of collagen fibers (*) consistent with the diagnosis of RPF ((a); Van-Gieson-stain, 100x). As shown for index patient 2, fibrosis was documented as bilateral symmetric solid retroperitoneal structures (-) after i.v application of 7 mL Gadovist ((b); T1 FLASH two-dimensional sequence in 1, 5 T MRI). next 3 years. Serum levels of IgG4 were repeatedly within normal range, and pancreas functions were not impaired. Systemic steroid treatment was gradually tapered to a dose of 10 mg daily and tacrolimus was continued, with stable sclerotic manifestations of chronic GVHD at the skin and buccal mucosa.
Out of 360 patients who received an allogeneic transplantation between 2001 and 2011 at the University of Goettingen, we here report two cases with the typical clinical and diagnostic findings of RPF. 2, 3 Outside the transplant setting, its etiology is mostly idiopathic, although associations with several diseases have been described, including systemic autoimmune or fibroinflammatory diseases, such as rheumatoid arthritis, small-and medium-sized vessel vasculitis or systemic lupus erythematosus, as well as radiation therapy, asbestos exposure and exposure to drugs such as b-blockers or ergotamine. 4 The index patients presented here had none of these risk factors, but had both developed extensive chronic GVHD preceding the RPF. RPF following HSCT in association with GVHD has been published once before, in a similar clinical setting. 5 Interestingly, in one of the cases presented here we had found elevated serum levels of IgG4. RPF in combination with elevated serum IgG4 levels is referred to as the clinicopathological entity of IgG4-related sclerosing disease (ISD). First introduced by Kamisawa in 2004, 6 ISD is a systemic disease affecting almost all organs, including pancreas, gall bladder, bile duct, liver and retroperitoneal tissue, and is histologically characterized by dense lymphoplasmacytic infiltrates with IgG4-bearing plasma cells and elevated serum IgG4 levels. ISD affects predominantly middle-aged and elderly men and responds well to corticosteroid therapy. 7 Overt autoimmune pancreatitis as one of its commonest manifestations was not noticed in our patient, although evidence of pancreatic organ damage was apparent. In this case, steroid therapy as a known effective treatment for ISD did not result in decrease of serum IgG4 levels. ISD in association with GVHD after allo-SCT has not been described yet.
In summary, we here present two cases of RPF as rare complications of chronic GVHD late after allogeneic HSCT, in one case associated with ISD.
